Red Flags Detected

  • Delisting (new) — Company faces potential delisting from Nasdaq if it cannot maintain minimum $1.00 bid price within compliance period(s).
  • Departure Of Cfo (new) — Chief Financial Officer is departing the company, triggering executive leadership transition risk during a period of stock price weakness.
NASDAQ: RANI Rani Therapeutics Holdings, Inc. 8-K

Rani Therapeutics receives Nasdaq delisting warning, CFO resigns amid Q1 2026 results

Filed May 15, 2026 · Period ending May 11, 2026 · ~1 min read

4 material changes detected in this filing.

Create a free account to read the full summary — it takes 30 seconds.

Partner

Trade RANI commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

Generated by AI · Jun 1, 2026 3:55 PM